The amount of revenue to be received upon the achievement of specified net sales thresholds for all licensed products.

No definition available.

Name:	glyc_AchievementOfSpecifiedNetSalesThresholdsForAllLicensedProducts
Namespace Prefix:	glyc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	glyc_ArrangementsAndNonarrangementTransactionsLineItems
Namespace Prefix:	glyc_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of development and regulatory specific approval milestones based on achievement of certain clinical and regulatory events.

+ References

No definition available.

+ Details

Name:	glyc_DevelopmentAndRegulatoryApprovalMilestonesClinicalAndRegulatoryEvents
Namespace Prefix:	glyc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The entitled royalty payments to be received based on a tiered percentage of annual net sales.

+ References

No definition available.

+ Details

Name:	glyc_TieredPercentageOfAnnualNetSales
Namespace Prefix:	glyc_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of up-front payment received under terms of the agreement.

+ References

No definition available.

+ Details

Name:	glyc_UpFrontPaymentReceived
Namespace Prefix:	glyc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	srt_CounterpartyNameAxis=glyc_ApollomicMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

License and Collaboration Agreements - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended
	Jan. 31, 2020	Mar. 31, 2020	Mar. 31, 2019
Research and License Agreements
Revenue		$ 9,000,000
Apollomics, Inc.
Research and License Agreements
Up-front payment received	$ 9,000,000
Milestones based on achievement of ceratin clinical and regulatory events	75,000,000
Milestone payment upon achievement of specified net sales thresholds for all licensed products	$ 105,000,000
Apollomics, Inc. \| Maximum
Research and License Agreements
Tiered percentage of annual net sales	15.00%